



www.MedChemExpress.com

Inhibitors, Screening Libraries, Proteins

CRFR

Corticotropin-releasing Factor Receptor

The CRFR (Corticotropin-releasing Factor Receptor, CRHR) belongs to the G-coupled receptor superfamily. Two receptor subtypes, CRF₁ receptor and CRF₂ receptor, and several splice variants for both receptor subtypes have been discovered. CRF itself has a greater affinity for CRF₁ receptors while urocortin 1 (Ucn 1) binds with high affinity to both receptors and Ucn 2 and Ucn 3 both preferentially bind to CRF₂ receptors.

Two CRF receptor subtypes are encoded by distinct genes which exhibit diverse alternative pre-mRNA splicing patterns resulting in multiple variants derived from partial or total exon deletions or insertions. With regard to the nine human CRF₁ variants, CRF_{1a-i'} described, CRF_{1a} being the main wild type functional receptor while the other isoforms may modulate CRF signaling. For the CRF₂, three functionally active splice variants, CRF_{2a-c'} have been described in humans.

CRFR Inhibitors, Agonists, Antagonists, Activators & Modulators

<p>Antisauvagine-30 (aSvq-30) Cat. No.: HY-P1107</p> <p>Antisauvagine-30 (aSvq-30) is a potent, competitive and selective CRF₂ receptor antagonist with K_d values of 1.4 nM and 153.6 nM for mouse CRF_{2b} and rat CRF₁ receptors, respectively.</p> <p><small>(D-Phe)-HLRKMEEKGEKGGKGMANRLLDT-NH₂</small></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Antisauvagine-30 TFA (aSvq-30 TFA) Cat. No.: HY-P1107A</p> <p>Antisauvagine-30 TFA (aSvq-30 TFA) is a potent, highly selective and competitive CRF₂ receptor peptidic antagonist. Antisauvagine-30 TFA exhibits a K_d of 1.4 nM and 150 nM for mCRFR2β and CRFR1, respectively.</p> <p><small>(D-Phe)-HLRKMEEKGEKGGKGMANRLLDT-NH₂ (TFA salt)</small></p> <p>Purity: 98.01% Clinical Data: No Development Reported Size: 5 mg, 10 mg</p>
<p>Cortagine Cat. No.: HY-P2287</p> <p>Cortagine is a specific corticotropin-releasing factor receptor subtype 1 (CRF1) agonist with an IC_{50} of 2.6 nM for rCRF1. Cortagine is an anxiolytic and antidepressive drug in the mouse model.</p> <p><small>(D)PFPISLDTLHLLREVLEMARAEQLAQAQAHNRLLDTA-NH₂</small></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg, 10 mg</p>	<p>Corticotropin-releasing factor (human) (Human CRF; Human corticotropin-releasing factor) Cat. No.: HY-P0086</p> <p>Corticotropin-releasing factor human (Human CRF) stimulates the synthesis and secretion of adrenocorticotropin in the anterior pituitary.</p> <p><small>SEEPFISLDTLHLLREVLEMARAEQLAQAQAHNRLLDTA-NH₂</small></p> <p>Purity: 98.44% Clinical Data: No Development Reported Size: 250 μg, 500 μg, 1 mg, 5 mg, 10 mg</p>
<p>Corticotropin-releasing factor (human) (acetate) (Human CRF acetate; Human corticotropin-releasing factor acetate) Cat. No.: HY-P0086A</p> <p>Corticotropin-releasing factor human acetate (Human CRF acetate) stimulates the synthesis and secretion of adrenocorticotropin in the anterior pituitary.</p> <p><small>SEEPFISLDTLHLLREVLEMARAEQLAQAQAHNRRLMEI-NH₂ (acetate salt)</small></p> <p>Purity: 98.25% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>CP 316311 Cat. No.: HY-14129</p> <p>CP 316311 is a potent and selective CRF1 receptor antagonist with an IC_{50} value of 6.8 nM.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>CP 376395 Cat. No.: HY-14130</p> <p>CP 376395 is a potent and selective Corticotropin releasing factor 1 (CRF1) receptor antagonist.</p>  <p>Purity: 99.71% Clinical Data: No Development Reported Size: 10 mM \times 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>	<p>CRF(6-33)(human) Cat. No.: HY-P1297</p> <p>CRF(6-33)(human) is a CRF binding protein (CRF-BP) ligand inhibitor. CRF(6-33)(human) competitively binds the CRF-BP but not the post-synaptic CRF receptors. CRF(6-33)(human) has anti-obesity effect.</p> <p><small>ISLDTLHLLREVLEMARAEQLAQAQHS</small></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>CRF(6-33)(human) TFA Cat. No.: HY-P1297A</p> <p>CRF(6-33)(human) TFA is a CRF binding protein (CRF-BP) ligand inhibitor. CRF(6-33)(human) TFA competitively binds the CRF-BP but not the post-synaptic CRF receptors. CRF(6-33)(human) TFA has anti-obesity effect.</p> <p><small>ISLDTLHLLREVLEMARAEQLAQAQHS (TFA salt)</small></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>CRF, bovine (Corticotropin Releasing Factor bovine) Cat. No.: HY-P1533</p> <p>CRF, bovine is a potent agonist of CRF receptor, and displaces [¹²⁵I-Tyr]ovine CRF with a K_i of 3.52 nM.</p> <p><small>GGEPFISLDTLHLLREVLEMTAQQAGAHNRPLLDVA-NH₂</small></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>CRF, bovine TFA (Corticotropin Releasing Factor bovine TFA)</p> <p>CRF, bovine (TFA) is a potent agonist of CRF receptor, and displaces [¹²⁵I]-Tyr]ovine CRF with a K_i of 3.52 nM.</p> <p>Purity: 96.50% Clinical Data: No Development Reported Size: 500 µg, 1 mg, 5 mg</p>	<p>Emicerfont (GW876008)</p> <p>Emicerfont is a corticotropin-releasing factor type 1 (CRF₁) receptor antagonist with an IC_{50} of 66 nM.</p> <p>Purity: >98% Clinical Data: Phase 2 Size: 1 mg, 5 mg</p>
<p>K41498</p> <p>K41498 is a potent and highly selective CRF2 receptor antagonist with K_i values of 0.66 nM, 0.62 nM and 425 nM for human CRF_{2α}, CRF_{2β} and CRF₁ receptors respectively.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>NBI-27914</p> <p>NBI-27914 is a potent and selective antagonist of CRFR1. The CRF receptors, CRFR1 and CRFR2, are members of the G protein-coupled receptor superfamily.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>NBI-27914 hydrochloride</p> <p>NBI-27914 (hydrochloride) is a selective Corticotropin-Releasing Factor 1 (CRF1) receptor antagonist with a K_i value of 1.7 nM.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>NVS-CRF38</p> <p>NVS-CRF38 is a novel corticotropin-releasing factor receptor 1 (CRF1) antagonist with low water solubility. IC_{50} value: Target: CRF1 antagonist.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Pexacerfont (BMS-562086)</p> <p>Pexacerfont is a selective corticotropin-releasing factor (CRF₁) receptor antagonist with IC_{50} of 6.1±0.6 nM for human CRF₁ receptor.</p> <p>Purity: 99.97% Clinical Data: Phase 3 Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg</p>	<p>R121919 (NBI30775)</p> <p>R121919 (NBI30775) is a potent small-molecule CRF1 receptor antagonist with a K_i of 2 to 5 nM for the CRF1 receptor and over 1000-fold weaker activity at the CRF2 receptor, CRF-binding protein, or 70 other receptor types.</p> <p>Purity: 99.84% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg</p>
<p>Sauvagine</p> <p>Sauvagine, a 40-amino-acid neuropeptide from the skin of the frog, is a mammalian CRF agonist. Sauvagine is effective at releasing ACTH from rat pituitary cells. Sauvagine possesses a number of pharmacological actions on diuresis, the cardiovascular system and endocrine glands.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Sauvagine TFA</p> <p>Sauvagine TFA, a 40-amino-acid neuropeptide from the skin of the frog, is a mammalian CRF agonist. Sauvagine TFA is effective at releasing ACTH from rat pituitary cells.</p> <p>Purity: 95.17% Clinical Data: No Development Reported Size: 5 mg</p>

<p>Urocortin II, human</p> <p style="text-align: right;">Cat. No.: HY-P1752</p>	<p>Urocortin II, human TFA</p> <p style="text-align: right;">Cat. No.: HY-P1752A</p>
<p>Urocortin II (human) is a selective endogenous peptide agonist of type-2 corticotropin-releasing factor (CRF2) receptor. For investigating the role of the CRF (2) receptor in ingestive behavior.</p> <p style="text-align: right;"><small>FTLSLDFPQLLQLEGGARRARRRGGATTNRLARLKHCH-NH₂</small></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Urocortin II, human (TFA) is a selective endogenous peptide agonist of type-2 corticotropin-releasing factor (CRF2) receptor. For investigating the role of the CRF (2) receptor in ingestive behavior.</p> <p style="text-align: right;"><small>FTLSLDFPQLLQLEGGARRARRRGGATTNRLARLKHCH-NH₂ (TFA salt)</small></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Urocortin III, mouse</p> <p style="text-align: right;">Cat. No.: HY-P1858</p>	<p>Urocortin III, mouse TFA</p> <p style="text-align: right;">Cat. No.: HY-P1858A</p>
<p>Urocortin III, mouse is a corticotropin-releasing factor (CRF)-related peptide. Urocortin III preferentially binds and activates CRF-R2. Urocortin III (Ucn3) is a known component of the behavioral stress response system.</p> <p style="text-align: right;"><small>FTLSLDFYPTNMLFNDKAKRLRKAARAAAGLMAQI-NH₂</small></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Urocortin III, mouse TFA is a corticotropin-releasing factor (CRF)-related peptide. Urocortin III preferentially binds and activates CRF-R2. Urocortin III (Ucn3) is a known component of the behavioral stress response system.</p> <p style="text-align: right;"><small>FTLSLDFYPTNMLFNDKAKRLRKAARAAAGLMAQI-NH₂ (TFA salt)</small></p> <p>Purity: 99.56% Clinical Data: No Development Reported Size: 1 mg, 5 mg, 10 mg</p>
<p>Urocortin, human (Urocortin (human); Human urocortin; Human urocortin I; Human urocortin I)</p> <p style="text-align: right;">Cat. No.: HY-P1295</p>	<p>Urocortin, rat (Urocortin (Rattus norvegicus); Rat urocortin;)</p> <p style="text-align: right;">Cat. No.: HY-P1296</p>
<p>Urocortin, human, a 40-aa neuropeptide, acts as a selective agonist of endogenous CRF₂ receptor, with K_s of 0.4, 0.3, and 0.5 nM for hCRF₁, rCRF_{2α} and mCRF_{2β}, respectively.</p> <p style="text-align: right;"><small>DNPSLSDLTTHLLTLELARTQSGRRRAEQNRPFDSV-NH₂</small></p> <p>Purity: 98.43% Clinical Data: No Development Reported Size: 500 µg, 1 mg, 5 mg</p>	<p>Urocortin, rat (Urocortin (Rattus norvegicus)) is a neuropeptide and a potent endogenous CRFR agonist with K_s of 13 nM, 1.5 nM, and 0.97 nM for human CRF₁, rat CRF_{2α} and mouse CRF_{2β}, respectively.</p> <p style="text-align: right;"><small>DDPPLSDLTTHLLTLELARTQSGRRRAEQNRPFDSV-NH₂</small></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 500 µg, 1 mg, 5 mg</p>
<p>Urocortin, rat TFA (Urocortin (Rattus norvegicus) (TFA); Rat urocortin TFA)</p> <p style="text-align: right;">Cat. No.: HY-P1296A</p>	<p>Urotensin I (Catostomus urotensin I)</p> <p style="text-align: right;">Cat. No.: HY-P1542</p>
<p>Urocortin, rat TFA (Urocortin (Rattus norvegicus) TFA) is a neuropeptide and a potent endogenous CRFR agonist with K_s of 13 nM, 1.5 nM, and 0.97 nM for human CRF₁, rat CRF_{2α} and mouse CRF_{2β}, respectively.</p> <p style="text-align: right;"><small>DDPPLSDLTTHLLTLELARTQSGRRRAEQNRPFDSV-NH₂ (TFA salt)</small></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Urotensin I (Catostomus urotensin I), a CRF-like neuropeptide, acts as an agonist of CRF receptor with pEC_{50}s of 11.46, 9.36 and 9.85 for human CRF₁, human CRF₂ and rat CRF_{2α} receptors in CHO cells, and K_s of 0.4, 1.8, and 5.7 nM for hCRF₁, rCRF_{2α} and mCRF_{2β} receptors, respectively.</p> <p style="text-align: right;"><small>NDPPLSDLTTHLLTLELARTQSGRRRAEQNRPFDSV-NH₂</small></p> <p>Purity: >98% Clinical Data: No Development Reported Size: 500 µg, 1 mg, 5 mg</p>
<p>Urotensin I TFA (Catostomus urotensin I TFA)</p> <p style="text-align: right;">Cat. No.: HY-P1542B</p>	<p>Verucerfont (GSK561679)</p> <p style="text-align: right;">Cat. No.: HY-14875</p>
<p>Urotensin I (Catostomus urotensin I) TFA, a CRF-like neuropeptide, acts as an agonist of CRF receptor with pEC_{50}s of 11.46, 9.36 and 9.85 for human CRF₁, human CRF₂ and rat CRF_{2α} receptors in CHO cells, and K_s of 0.4, 1.8, and 5.7 nM for hCRF₁, rCRF_{2α} and...</p> <p style="text-align: right;"><small>NDPPLSDLTTHLLTLELARTQSGRRRAEQNRPFDSV-NH₂ (TFA salt)</small></p> <p>Purity: 98.29% Clinical Data: No Development Reported Size: 500 µg</p>	<p>Verucerfont is a corticotropin-releasing factor receptor 1 (CRF1) antagonist with IC_{50}s of ~6.1, >1000 and >1000nM for CRF1, CRF2, and CRF-BP, respectively.</p> <p style="text-align: right;"></p> <p>Purity: 98.67% Clinical Data: Phase 2 Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</p>

α -Helical CRF(9-41)

Cat. No.: HY-P1294

α -Helical CRF(9-41) is a competitive **CRF2 receptor** antagonist with K_b of ~100 nM.
 α -Helical CRF(9-41) is also a partial agonist of **CRF1 receptor** with an EC_{50} of 140 nM.

DLTFHLREMLEMKKAEQEGAEQALNRLLEEANH₂

Purity: >98%

Clinical Data: No Development Reported

Size: 5 mg, 10 mg

α -Helical CRF(9-41) TFA

Cat. No.: HY-P1294A

α -Helical CRF(9-41) TFA is a competitive **CRF2 receptor** antagonist with K_b of ~100 nM.
 α -Helical CRF(9-41) TFA is also a partial agonist of **CRF1 receptor** with an EC_{50} of 140 nM.

DLTFHLREMLEMKKAEQEGAEQALNRLLEEANH₂ (TFA salt)

Purity: >98%

Clinical Data: No Development Reported

Size: 1 mg, 5 mg